Clinicopathological findings, treatment response and predictors of long-term outcome in a cohort of lupus nephritis patients managed according to the Euro-lupus regime: a retrospective analysis in Sri Lanka

Nalaka Herath, Neelakanthi Ratnatunga, Kosala Weerakoon, Abdul Wazil, Nishantha Nanayakkara, Nalaka Herath, Neelakanthi Ratnatunga, Kosala Weerakoon, Abdul Wazil, Nishantha Nanayakkara

Abstract

Background: Despite the improvement in survival of patients with lupus nephritis (LN) globally, there is sparse data from Sri Lanka (SL). The current study aims to describe the clinicopathological findings, treatment response and predictors of long-term outcome of patients with WHO class III-IV LN in SL, managed according to the Euro-lupus regime.

Results: Of 72 patients, 64 were females. In half of them, LN was diagnosed within the 1st year of the illness. The most common presenting feature was sub-nephrotic proteinuria. Sixteen and twenty patients had nephrotic syndrome and abnormal renal function respectively at the time of diagnosis. Fifty-four patients (75%) responded to the Euro-lupus regimen [CR, 20 (28%); PR, 34(47%)]. Later at 6 months, 65 patients (90%) achieved remission [CR, 31(43%); PR, 34 (47%)]. Seven patients experienced treatment failure. During the total duration of follow up, 54 patients remained in complete or partial remission, 26 developed renal relapses, and 19 suffered severe infective episodes. Renal relapses were more common in people who achieved partial remission than complete remission. The long term renal outcome was not associated with age, sex, severity of proteinuria, class of LN or initial renal function. Patients who achieved remission at 6 months had a good long-term outcome.

Conclusions: The demographic and clinical features of WHO class III and IV LN in Sri Lankan patients were similar to that reported in the global literature. 75% of patients responded to the Euro-lupus regimen. Therefore, this regime is a suitable initial regimen for LN patients in SL. Good long-term renal outcome can be predicted by early response to therapy. Further studies are necessary to explore better treatment options for patients who fail to achieve remission during initial therapy.

Keywords: Lupus nephritis; Relapses; Remission; SLE; Sri Lanka.

References

    1. Cameron JS. Lupus nephritis. J Am Soc Nephrol. 1999;10:413–424.
    1. Costenbader KH, Desai A, Alarcón GS, Hiraki LT, Shaykevich T, Brookhart MA, et al. Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006. Arthritis Rheum. 2011;63:1681–1688. doi: 10.1002/art.30293.
    1. Ward MM. Access to care and the incidence of endstage renal disease due to systemic lupus erythematosus. J Rheumatol. 2010;37:1158–1163. doi: 10.3899/jrheum.091199.
    1. Faurschou M, Dreyer L, Kamper A-L, Starklint H, Jacobsen S. Long-term mortality and renal outcome in a cohort of 100 patients with lupus nephritis. Arthritis Care Res (Hoboken). 2010;62:873–880. doi: 10.1002/acr.20116.
    1. Houssiau FA, Vasconcelos C, D’Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis. 2010;69:61–64. doi: 10.1136/ard.2008.102533.
    1. Galapatthy P, Wazeel AN, Nanayakkara S, Sheriff R. Clinical features of systemic lupus erythematosus in Sri Lankan patients: results from a lupus clinic. Ceylon Med J. 2000;45:162–165.
    1. Houssiau FA, Vasconcelos C, D’Cruz D, Sebastiani GD, de Garrido Ed ER, Danieli MG, et al. Immunosuppressive therapy in lupus nephritis: the Euro-lupus nephritis trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002;46:2121–2131. doi: 10.1002/art.10461.
    1. Dhir V, Aggarwal A, Lawrence A, Agarwal V, Misra R. Long-term outcome of lupus nephritis in Asian Indians. Arthritis Care Res (Hoboken). 2012;64:713–720. doi: 10.1002/acr.21597.
    1. Chan T-M, Tse K-C, Tang CS-O, Mok M-Y, Li F-K, Hong Kong Nephrology Study Group Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol. 2005;16:1076–1084. doi: 10.1681/ASN.2004080686.
    1. Moroni G, Quaglini S, Gallelli B, Banfi G, Messa P, Ponticelli C. The long-term outcome of 93 patients with proliferative lupus nephritis. Nephrol Dial Transpl. 2007;22:2531–2539. doi: 10.1093/ndt/gfm245.
    1. Mok CC, Ho CTK, Chan KW, Lau CS, Wong RWS. Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine. Arthritis Rheum. 2002;46:1003–1013. doi: 10.1002/art.10138.
    1. Bono L, Cameron JS, Hicks JA. The very long-term prognosis and complications of lupus nephritis and its treatment. QJM. 1999;92:211–218. doi: 10.1093/qjmed/92.4.211.
    1. Houssiau FA, Vasconcelos C, D’Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-lupus nephritis trial. Arthritis Rheum. 2004;50:3934–3940. doi: 10.1002/art.20666.
    1. Austin HA, Boumpas DT, Vaughan EM, Balow JE. Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int. 1994;45:544–550. doi: 10.1038/ki.1994.70.
    1. Austin HA, Boumpas DT, Vaughan EM, Balow JE. High-risk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients. Nephrol Dial Transpl. 1995;10:1620–1628.
    1. Levey AS, Lan SP, Corwin HL, Kasinath BS, Lachin J, Neilson EG, et al. Progression and remission of renal disease in the Lupus Nephritis Collaborative Study. Results of treatment with prednisone and short-term oral cyclophosphamide. Ann Intern Med. 1992;116:114–123. doi: 10.7326/0003-4819-116-2-114.
    1. Fraenkel L, MacKenzie T, Joseph L, Kashgarian M, Hayslett JP, Esdaile JM. Response to treatment as a predictor of longterm outcome in patients with lupus nephritis. J Rheumatol. 1994;21:2052–2057.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe